1. Home
  2. ARVN vs SHEN Comparison

ARVN vs SHEN Comparison

Compare ARVN & SHEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Arvinas Inc.

ARVN

Arvinas Inc.

SELL

Current Price

$6.82

Market Cap

600.2M

Sector

Health Care

ML Signal

SELL

Logo Shenandoah Telecommunications Co

SHEN

Shenandoah Telecommunications Co

HOLD

Current Price

$10.34

Market Cap

640.6M

ML Signal

HOLD

Company Overview

Basic Information
Metric
ARVN
SHEN
Founded
2015
1902
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Telecommunications Equipment
Sector
Health Care
Telecommunications
Exchange
Nasdaq
Nasdaq
Market Cap
600.2M
640.6M
IPO Year
2018
1994

Fundamental Metrics

Financial Performance
Metric
ARVN
SHEN
Price
$6.82
$10.34
Analyst Decision
Buy
Buy
Analyst Count
16
2
Target Price
$13.93
★ $27.50
AVG Volume (30 Days)
772.6K
★ 1.1M
Earning Date
11-04-2026
10-28-2026
Dividend Yield
N/A
★ 1.05%
EPS Growth
★ 58.84
N/A
EPS
★ 1.70
N/A
Revenue
$262,600,000.00
★ $357,854,000.00
Revenue This Year
$12.76
$4.75
Revenue Next Year
N/A
$5.17
P/E Ratio
$4.04
★ N/A
Revenue Growth
N/A
★ 9.08
52 Week Low
$6.80
$9.67
52 Week High
$14.22
$17.35

Technical Indicators

Market Signals
Indicator
ARVN
SHEN
Relative Strength Index (RSI) 28.59 33.46
Support Level N/A N/A
Resistance Level $8.52 $12.61
Average True Range (ATR) 0.30 0.57
MACD -0.03 -0.09
Stochastic Oscillator 8.61 8.29

Price Performance

Historical Comparison
ARVN
SHEN

About ARVN Arvinas Inc.

Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.

About SHEN Shenandoah Telecommunications Co

Shenandoah Telecommunications Co with its subsidiaries, provides various broadband communication products and services via its wireless, cable, fiber optic, and fixed wireless networks to customers in the Mid-Atlantic United States. The company operates through one business unit: Broadband. The broadband segment provides broadband Internet, video, and voice services to residential and commercial customers. The broadband segment generates the vast majority of the company's revenue, with the bulk of sales flowing from residential and small, and medium businesses within the broadband unit.

Share on Social Networks: